Suppr超能文献

毛细胞白血病治疗期间胃癌的不寻常表现:探究这一罕见现象的病因学基础。

Unusual presentation of gastric cancer during treatment of hairy cell leukemia: Exploring the etiological basis of this rare phenomenon.

作者信息

Tariq Shahan, Bin Hamid Muhammad Ammar, Rahman Nazia, Oleary Lindsey, Wong Kristine, Sehbai Aasim

机构信息

Department of Hematology/Oncology, Regional Medical Center (RMC), Anniston, AL, 36207, USA.

Department of Internal Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD, 57069, USA.

出版信息

Cancer Pathog Ther. 2023 Jan 12;1(2):146-148. doi: 10.1016/j.cpt.2023.01.003. eCollection 2023 Apr.

Abstract

Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder. Patients typically present with cytopenia and splenomegaly. We describe the case of a 78-year-old patient with refractory HCL who acutely developed a cystic lesion on the back while receiving moxetumomab pasudotox therapy. Biopsy of the lesion revealed the presence of adenocarcinoma, which prompted a detailed evaluation resulting in a diagnosis of stage IV gastric cancer. Nevertheless, to establish any association between moxetumomab pasudotox therapy and secondary cancer development, a satisfactory number of studies need to be conducted.

摘要

毛细胞白血病(HCL)是一种罕见的B细胞淋巴增殖性疾病。患者通常表现为血细胞减少和脾肿大。我们描述了一例78岁难治性HCL患者的病例,该患者在接受莫西妥莫单抗帕苏妥治疗时背部急性出现一个囊性病变。病变活检显示存在腺癌,这促使进行详细评估,最终诊断为IV期胃癌。然而,要确定莫西妥莫单抗帕苏妥治疗与继发性癌症发生之间的任何关联,还需要进行足够数量的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75ef/10846291/4e95798cee08/gr1.jpg

相似文献

1
Unusual presentation of gastric cancer during treatment of hairy cell leukemia: Exploring the etiological basis of this rare phenomenon.
Cancer Pathog Ther. 2023 Jan 12;1(2):146-148. doi: 10.1016/j.cpt.2023.01.003. eCollection 2023 Apr.
2
Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
Cancer Chemother Pharmacol. 2019 Aug;84(2):255-263. doi: 10.1007/s00280-019-03875-6. Epub 2019 May 27.
3
Moxetumomab pasudotox for the treatment of hairy cell leukemia.
Expert Opin Biol Ther. 2019 Jun;19(6):501-508. doi: 10.1080/14712598.2019.1614558. Epub 2019 May 10.
5
Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use.
Clin Drug Investig. 2021 Sep;41(9):829-834. doi: 10.1007/s40261-021-01069-8. Epub 2021 Aug 12.
6
Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia.
Expert Rev Hematol. 2019 Sep;12(9):707-714. doi: 10.1080/17474086.2019.1643231. Epub 2019 Aug 1.
7
Lytic Bone Lesion: An Unusual Presentation of Hairy Cell Leukemia.
Cureus. 2021 Jan 28;13(1):e12959. doi: 10.7759/cureus.12959.
8
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
Ann Pharmacother. 2019 Sep;53(9):922-932. doi: 10.1177/1060028019836775. Epub 2019 Mar 6.
9
Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia.
Clin J Oncol Nurs. 2019 Jun 1;23(3):E52-E59. doi: 10.1188/19.CJON.E52-E59.
10
Advances in the Treatment of Hairy Cell Leukemia Variant.
Curr Treat Options Oncol. 2022 Jan;23(1):99-116. doi: 10.1007/s11864-021-00927-z. Epub 2022 Feb 18.

引用本文的文献

1
Advanced molecular diagnostics: Driving precision in hematological malignancies.
Cancer Pathog Ther. 2024 Nov 6;3(4):276-277. doi: 10.1016/j.cpt.2024.09.001. eCollection 2025 Jul.
2
Rare Clinical Symptoms in Hairy Cell Leukemia: An Overview.
Cancers (Basel). 2024 Sep 1;16(17):3054. doi: 10.3390/cancers16173054.

本文引用的文献

1
Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Biomolecules. 2020 Aug 3;10(8):1140. doi: 10.3390/biom10081140.
2
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.
Blood Cancer J. 2020 May 27;10(5):62. doi: 10.1038/s41408-020-0328-z.
3
Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
Cancer Chemother Pharmacol. 2019 Aug;84(2):255-263. doi: 10.1007/s00280-019-03875-6. Epub 2019 May 27.
4
Hairy cell leukemia: present and future directions.
Leuk Lymphoma. 2019 Dec;60(12):2869-2879. doi: 10.1080/10428194.2019.1608536. Epub 2019 May 9.
5
Moxetumomab Pasudotox: First Global Approval.
Drugs. 2018 Nov;78(16):1763-1767. doi: 10.1007/s40265-018-1000-9.
6
Risk Factors for Gastric Cancer: A Systematic Review.
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):591-603. doi: 10.22034/APJCP.2018.19.3.591.
7
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.
Blood. 2018 May 24;131(21):2331-2334. doi: 10.1182/blood-2017-09-803072. Epub 2018 Feb 27.
10
Long-term results for pentostatin and cladribine treatment of hairy cell leukemia.
Leuk Lymphoma. 2011 Jun;52 Suppl 2:21-4. doi: 10.3109/10428194.2011.565093.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验